Role of Targeted Therapy in Advanced Melanoma Treatment

2024 ASCO® Annual Meeting Insights Hub
Avatar

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuvant Treatments, 1L Metastatic & Anti-PD-1 Refractory Disease"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Zeynep Eroglu
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Zeynep Eroglu
339 views
July 5, 2024
Comments 0
Login to view comments. Click here to Login
12:31

Systemic Treatment Approaches for High-Risk Melanoma

Gabriela Cinat

186 views
07:23

Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

Mees Egeler

330 views
14:23

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi

403 views
46:28

2024 Melanoma Update: Insights Into Sentinel Node Evaluation

Scripps Health

M. Ross

132 views
35:23

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

864 views
22:58

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

790 views
25:44

Melanoma in the Molecular Age - Part 1: New Tools for Diagnosis, Pro…

Scripps Health

G. Hosler

423 views
10:01

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

652 views
24:40

Pathology of Melanoma

Scripps Health

B. Kelley

381 views
03:55

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

533 views
11:05

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

552 views
14:42

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

611 views
13:55

Utilization of COMBI-APlus Data in Clinical Practice: Adapted Pyrexi…

Northwestern Medicine Oncology and Hematology

S. Chandra

926 views